A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE (R)

作者：von Krempelhuber Alfred^*; Vollmar Jens; Pokorny Rolf; Rapp Petra; Wulff Niels; Petzold Barbara; Handley Amanda; Mateo Lyn; Sier**ol Henriette; Kollaritsch Herwig; Chaplin Paul

来源：Vaccine, 2010, 28(5): 1209-1216.

DOI：10.1016/j.vaccine.2009.11.030

• Smallpox
• Vaccination
• MVA
• Vaccinia

IMVAMUNE (R) is a Modified Vaccinia Ankara (MVA)-based virus that is being developed as a safer 3rd generation smallpox vaccine. In order to determine the optimal dose for further development, a double-blind, randomized Phase II trial was performed testing three different doses of IMVAMUNE (R) in 164 healthy volunteers. All three IMVAMUNE (R) doses displayed a favourable safety profile, with local reactions as the most frequent observation. The 1 x 10(8) TCID(50) IMVAMUNE (R) dose induced a total antibody response in 94% of the subjects following the first vaccination and the highest peak seroconversion rates by ELISA (100%) and PRNT (71%). This IMVAMUNE (R) dose was considered to be optimal for the further clinical development of this highly attenuated poxvirus as a safer smallpox vaccine.

• 出版日期2010-2-3